登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《JAMA，5月1日，Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for COVID-19》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-05-02

  • Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)

    Nicholas J. Mercuro, PharmD, BCIDP1; Christina F. Yen, MD2; David J. Shim, MD, PhD3; et al Timothy R. Maher, MD4; Christopher M. McCoy, PharmD, BCPS(AQ-ID), BCIDP1; Peter J. Zimetbaum, MD3,4; Howard S. Gold, MD2

    Author Affiliations Article Information

    JAMA Cardiol. Published online May 1, 2020. doi:10.1001/jamacardio.2020.1834

    Abstract

    Importance Administration of hydroxychloroquine with or without azithromycin for the treatment of coronavirus disease 2019 (COVID-19)–associated pneumonia carries increased risk of corrected QT (QTc) prolongation and cardiac arrhythmias.

    Objective To characterize the risk and degree of QT prolongation in patients with COVID-19 in association with their use of hydroxychloroquine with or without concomitant azithromycin.

  • 原文来源：https://jamanetwork.com/journals/jamacardiology/fullarticle/2765631?resultClick=1
21浏览量
原文链接
相关报告

  • 《JAMA，5月1日，Assessment of QT Intervals in a Case Series of Patients With COVID-19 Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-05-02
    • Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit Francis Bessière, MD, PhD1,2; Hugo Roccia, MD3; Antoine Delinière, MD1,2; et al Rome Charrière, MD4; Philippe Chevalier, MD, PhD1,2; Laurent Argaud, MD, PhD3; Martin Cour, MD, PhD2 Author Affiliations Article Information JAMA Cardiol. Published online May 1, 2020. doi:10.1001/jamacardio.2020.1787 The novel coronavirus disease 2019 (COVID-19) outbreak is an ongoing situation caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1 Studies in patients with mild to moderate COVID-19 symptoms have suggested benefits of hydroxychloroquine alone or in combination with azithromycin against SARS-CoV-2 and raised hope for treating the disease.2 As a result, these treatments are increasingly used off-label for patients with COVID-19, including for those in intensive care units (ICUs).2,3 However, both medications are known to induce QT prolongation via a human Ether-à-go-go–related gene potassium channel blockade, which can promote life-threatening ventricular arrhythmias.4,5 Safety data for these treatments are largely lacking for patients with COVID-19. This is even more relevant for critically ill patients who are particularly exposed to electrolyte imbalance and/or drugs leading to an increased risk of QT prolongation.6 Therefore, we aimed to examine the safety of hydroxychloroquine with or without azithromycin regarding QT interval in ICU patients with COVID-19.
    18浏览量
    原文链接

  • 《Nature，4月24日，The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-25
    • The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin Ehud Chorin, Matthew Dai, Eric Shulman, Lalit Wadhwani, Roi Bar-Cohen, Chirag Barbhaiya, Anthony Aizer, Douglas Holmes, Scott Bernstein, Michael Spinelli, David S. Park, Larry A. Chinitz & Lior Jankelson Nature Medicine (2020) To the Editor — The SARS-CoV-2 pandemic has caused more than 1.6 million positive cases and more than 95,000 confirmed deaths as of 10 April 2020 (ref. 1). Although there are no approved drugs to prevent or treat SARS-CoV-2 infection2, a recent report suggested that the combination of hydroxychloroquine and azithromycin (HY/AZ) may have a favorable effect on the clinical outcomes and viral loads of infected patients3; this resulted in massive adoption of the regimen by clinicians worldwide. However, both medications have been independently shown to increase the risk in other populations for QT-interval prolongation, drug-induced torsades de pointes (a form of polymorphic ventricular tachycardia) and drug-induced sudden cardiac death.
    18浏览量
    原文链接